Ena Prosser
Partner @ Fountain Healthcare Partners
Dublin, Ireland
Ena Prosser is a Series A investor at Fountain Healthcare Partners in Dublin focused on Health Care and Biotechnology. Dr Ena Prosser is a Partner in Fountain Healthcare Partners. Ena was part of the team that raised Fountain Healthcare Partners Fund 1 in 2008. Ena is a PhD Immunologist by training and she has a broad background in international alliance and intellectual property management. She has led rigorous due diligence projects on technologies and productswithin the Specialty Pharma, diagnostic, device and biotechnology areas.Ena was formerly Director of Enterprise Ireland BIO. In this role, she led a large team to identify, fund, protect and exploit relevant Intellectual Property, commercialise lifescience technologies and review investment opportunities in R&D.Prior to Enterprise Ireland, Ena held various R&D and project management roles within Elan Corporation and had extensive involvement in drug delivery development, licensing and acquisition projects over a 9-year period. Ena has a strong innovation policy background and is a member of the Irish Government Innovation Taskforce in Intellectual Property, as well as being a council member of the Irish BioIndustry Association. She led the investments and is a board member of Genable Ltd, and Trino Therapeutics Ltd. Ena works closely with Ireland’s leading ophthalmology research charity Fighting Blindness. Ena is an Adjunct Professor at University College Dublin and she is a member of the Institute of Directors (Cert. Comp Dir).
- Total investments:
- 8
- Last investment:
- Lead investor:
- 88%
Last updated:
For AI agents: llms.txt
Industries Ena Prosser invests in
Stages Ena Prosser invests in
Countries Ena Prosser invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 6 (75%)
- Biotechnology 6 (75%)
- Medical 4 (50%)
- Genetics 1 (13%)
- Therapeutics 1 (13%)
Stage
- Series A 3 (38%)
- Series B 3 (38%)
- Series C 1 (13%)
- Series D 1 (13%)
Country
- Ireland 3 (38%)
- France 1 (13%)
- Belgium 1 (13%)
- Switzerland 1 (13%)
- United Kingdom 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases. | $43.5M / Series A / May 15, 2023 | ||
| Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strongexpertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates. | $9.5M / Series A / Sep 09, 2021 | ||
| Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide (LR12), with applications in a number of therapeutic indications such as septic shock or myocardial infarction.Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases. | $5.5M / Series B / Feb 11, 2020 | ||
| NeRRe Therapeutics Ltd. operates as a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists. The company was founded in 2012 and is based in Stevenage, United Kingdom. | $28.6M / Series B / Jan 05, 2017 | ||
| Trino is a drug discovery and early drug development company focused on anti-inflammatory therapeutics. The company is developing drug candidates from a novel, proprietary, class of drugs based on indane dimers derived from a Taiwanese fern. Its lead candidate is a potential first-in-class drug for the treatment of inflammatory bowel disease(IBD), which could be used in both ulcerative colitis (UC) and Crohn’s disease (CD). Trino’s drug class also offers promising candidates with a broad anti-inflammatory activity that could be suitable for applications in dermatology, pulmonary and auto-immune disease. | $9.9M / Series A / May 28, 2013 | ||
| Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease.The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan,Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005. | $11.5M / Series D / Oct 28, 2010 | ||
| Genable Technologies Ltd. is a privately held, venture backed, Dublin (Ireland) based bio-pharmaceutical company developing new gene medicines to treat "dominant" genetic diseases based on the pioneering work of Professor Jane Farrar, Dr Paul Kenna & Professor Peter Humphries.Genable utilizes well-established, clinically safe& effective AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene copies and replaces this with a gene subtly altered to become refractory to suppression but still encoding a normal wild type protein.The combination of suppression and replacement (S&R) overcomes the significant hurdle in dominant disease of mutation variability by eliminating the need to target specific mutations in a wide range of disorders. Genable's technology is protected by a broad suite of granted patents and patent applications in the USA, EU and worldwide. | $5.5M / Series B / Nov 10, 2009 | ||
| Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease.The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan,Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005. | $17.3M / Series C / Jul 22, 2009 |
Co-Investors
Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.
Fountain Healthcare Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aidan King
Co-Founder & Managing Partner
|
|||
|
Ena Prosser
Partner
|
|||
Justin Lynch
Partner & CFO
|
|||
Manus Rogan
Co-Founder & Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ena Prosser invest in?
Ena Prosser invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ena Prosser?
Public channels for Ena Prosser include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ena Prosser last invest?
The most recent investment recorded for Ena Prosser closed in May 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
